NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Novartis
Children's Oncology Group
Sir Mortimer B. Davis - Jewish General Hospital
Helsinki University Central Hospital
Gruppo Italiano Malattie EMatologiche dell'Adulto
Il-Yang Pharm. Co., Ltd.